A Postmarketing Clinical Experience Study of Metadate® CD

Autor: D'Imperio Jm, Birdsall D, Hatch Sj, Dirksen Sj

Publikováno v: Current Medical Research and Opinion. 18:371-380

The objective of the study was to investigate the effectiveness and safety of Metadate CD (methylphenidate HCl, USP) Extended Release Capsules in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), in actual clinical practice.This was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99213f89f6a7e24a00597f7896c136f2
https://doi.org/10.1185/030079902125001100

Comparison of the clinical efficacy of twice-daily RITALIN and once-daily EQUASYM XL with placebo in children with attention deficit/hyperactivity disorder.

Autor: Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M

Publikováno v: European Child & Adolescent Psychiatry; Dec2006, Vol. 15 Issue 8, p450-459, 10p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate.

Autor: Sonuga-Barke EJS; Dr. Sonuga-Barke is with the Developmental Brain-Behaviour Unit, University of Southampton, Southampton, UK; Mr. Coghill is with the Department of Psychiatry, The University of Dundee, Dundee, UK; Dr. Markowitz is with the Departments of Pharmaceutical Sciences and Psychiatry and Behavioral Medicine, Medical University of South Carolina, Charleston; Dr. Swanson is with the Child Development Center (UCI-CDC), University of California at Irvine; Dr. Vandenberghe is with UCB Pharma, Brussels, Belgium; and Mr. Hatch is with Simon Hatch Consulting Inc., Pittsford, NY. Electronic address: ejb3@soton.ac.uk., Coghill D; Dr. Sonuga-Barke is with the Developmental Brain-Behaviour Unit, University of Southampton, Southampton, UK; Mr. Coghill is with the Department of Psychiatry, The University of Dundee, Dundee, UK; Dr. Markowitz is with the Departments of Pharmaceutical Sciences and Psychiatry and Behavioral Medicine, Medical University of South Carolina, Charleston; Dr. Swanson is with the Child Development Center (UCI-CDC), University of California at Irvine; Dr. Vandenberghe is with UCB Pharma, Brussels, Belgium; and Mr. Hatch is with Simon Hatch Consulting Inc., Pittsford, NY., Markowitz JS; Dr. Sonuga-Barke is with the Developmental Brain-Behaviour Unit, University of Southampton, Southampton, UK; Mr. Coghill is with the Department of Psychiatry, The University of Dundee, Dundee, UK; Dr. Markowitz is with the Departments of Pharmaceutical Sciences and Psychiatry and Behavioral Medicine, Medical University of South Carolina, Charleston; Dr. Swanson is with the Child Development Center (UCI-CDC), University of California at Irvine; Dr. Vandenberghe is with UCB Pharma, Brussels, Belgium; and Mr. Hatch is with Simon Hatch Consulting Inc., Pittsford, NY., Swanson JM; Dr. Sonuga-Barke is with the Developmental Brain-Behaviour Unit, University of Southampton, Southampton, UK; Mr. Coghill is with the Department of Psychiatry, The University of Dundee, Dundee, UK; Dr. Markowitz is with the Departments of Pharmaceutical Sciences and Psychiatry and Behavioral Medicine, Medical University of South Carolina, Charleston; Dr. Swanson is with the Child Development Center (UCI-CDC), University of California at Irvine; Dr. Vandenberghe is with UCB Pharma, Brussels, Belgium; and Mr. Hatch is with Simon Hatch Consulting Inc., Pittsford, NY., Vandenberghe M; Dr. Sonuga-Barke is with the Developmental Brain-Behaviour Unit, University of Southampton, Southampton, UK; Mr. Coghill is with the Department of Psychiatry, The University of Dundee, Dundee, UK; Dr. Markowitz is with the Departments of Pharmaceutical Sciences and Psychiatry and Behavioral Medicine, Medical University of South Carolina, Charleston; Dr. Swanson is with the Child Development Center (UCI-CDC), University of California at Irvine; Dr. Vandenberghe is with UCB Pharma, Brussels, Belgium; and Mr. Hatch is with Simon Hatch Consulting Inc., Pittsford, NY., Hatch SJ; Dr. Sonuga-Barke is with the Developmental Brain-Behaviour Unit, University of Southampton, Southampton, UK; Mr. Coghill is with the Department of Psychiatry, The University of Dundee, Dundee, UK; Dr. Markowitz is with the Departments of Pharmaceutical Sciences and Psychiatry and Behavioral Medicine, Medical University of South Carolina, Charleston; Dr. Swanson is with the Child Development Center (UCI-CDC), University of California at Irvine; Dr. Vandenberghe is with UCB Pharma, Brussels, Belgium; and Mr. Hatch is with Simon Hatch Consulting Inc., Pittsford, NY.

Publikováno v: Journal of the American Academy of Child and Adolescent Psychiatry [J Am Acad Child Adolesc Psychiatry] 2007 Jun; Vol. 46 (6), pp. 701-710.